文献速递血栓与止血

卵巢癌患者静脉血栓栓塞发生时机:丹麦全国队列研究

The timing of venous thromboembolism in ovarian cancer patients: A nationwide Danish cohort study.
PubMed 文献 · J Thromb Haemost · 2021-02-08

该研究基于丹麦妇科癌症数据库2005至2014年4991例上皮性卵巢癌患者,随访至静脉血栓栓塞或删失,中位随访2.9年。共登记551例VTE事件,诊断后2年累积发生率为7.2%,第一年风险最高。既往VTE、骨盆大手术和化疗与VTE风险升高相关,晚期分期为独立肿瘤相关危险因素。

要点

  • 上皮性卵巢癌诊断后第一年VTE风险最高,2年累积发生率为7.2%。
  • 既往VTE和骨盆大手术与VTE风险升高约3倍相关。
  • 化疗期间应考虑血栓预防,晚期分期为独立危险因素。

核心结论

  • 上皮性卵巢癌患者VTE风险高,尤其诊断后第一年内,骨盆大手术与化疗与VTE强相关,结果支持化疗期间进行血栓预防。

研究设计与样本

  • 丹麦全国队列研究,纳入丹麦妇科癌症数据库2005至2014年4991例上皮性卵巢癌患者,随访至VTE或删失,中位随访2.9年。
  • 手术、化疗和VEGF抑制剂作为时间依存暴露纳入Cox比例风险回归模型。

主要发现

  • 4991例患者中共登记551例VTE事件。
  • 诊断后2年VTE累积发生率为7.2%,第一年风险最高。
  • 既往VTE的HR为3.26(95%CI 2.42-4.39),骨盆大手术HR为3.21(95%CI 2.29-4.50)。
  • 化疗HR为1.91(95%CI 1.56-2.33),VEGF抑制剂HR为1.05(95%CI 0.57-1.93)。
  • 透明细胞组织学HR为1.46(95%CI 0.97-2.20),FIGO III–IV期HR为2.42(95%CI 1.93-3.03)。

关键数值与推荐

  • VTE风险升高的因素包括既往VTE(HR 3.26)、骨盆大手术(HR 3.21)、化疗(HR 1.91)和FIGO III–IV期(HR 2.42)。

临床怎么用

  • 对上皮性卵巢癌患者应关注诊断后第一年的VTE风险,尤其接受骨盆大手术或化疗者,可考虑血栓预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIM: Venous thromboembolism (VTE) is associated with excess mortality and morbidity in cancer, and is influenced by patient-, tumor-, and treatment-related factors. We aimed to investigate the impact of such factors in a national cohort of patients with epithelial ovarian cancer (EOC). METHODS: Patients in the Danish Gynecologic Cancer Database (DGCD) with EOC from 2005 to 2014 were followed from time of diagnosis to VTE, or censoring. Surgery, chemotherapy, and vascular epithelial growth factor (VEGF)-inhibitors were included as time-varying exposures in Cox proportional hazard regression models. RESULTS: A total of 551 VTE events were registered in 4991 EOC patients. Median follow-up time was 2.9 years. The 2-year cumulative incidence of VTE was 7.2%. Patients were at highest risk during the first year after EOC diagnosis. Previous VTE was associated with a hazard ratio (HR) of 3.26 (95% confidence interval [CI] 2.42-4.39). Exposure to major pelvic surgery was associated with a HR of 3.21 (95% CI 2.29-4.50). Exposure to chemotherapy or (VEGF)-inhibitors were associated with HRs of 1.91 (95% CI 1.56-2.33) and 1.05 (95% CI 0.57-1.93), respectively. Hazard ratios for patients with clear cell histopathology was 1.46 (95% CI 0.97-2.20) and 2.42 for International Federation of Gynaecology and Obstetrics stage III--IV (95% CI 1.93-3.03). CONCLUSIONS: EOC is associated with a high risk of VTE, particularly within the first year after diagnosis. Major pelvic surgery and chemotherapy were strongly associated with VTE. Person-related risk factors were increasing age and previous VTE. Advanced stage was an independent tumor-related risk factor. These findings support the indication for thrombosis prophylaxis during chemotherapy.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Strøm Kahr H, Christiansen OB, Juul Riddersholm S, et al. The timing of venous thromboembolism in ovarian cancer patients: A nationwide Danish cohort study. J Thromb Haemost. 2021. PMID: 33420762. doi:10.1111/jth.15235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。